132 related articles for article (PubMed ID: 3864001)
1. Methotrexate-vindesine association in leukemia: pharmacokinetic study.
Tubiana N; Lena N; Barbet J; Imbert AM; Lejeune C; Maraninchi D; Sainty D; Sebahoun G; Gastaut JA; Cano JP
Med Oncol Tumor Pharmacother; 1985; 2(2):99-102. PubMed ID: 3864001
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate-vindesine association in head and neck cancer: modification of methotrexate's hydroxylation in presence of vindesine.
Bore P; Lena N; Imbert AM; Favre R; Cano JP; Meyer G; Carcassonne Y
Cancer Chemother Pharmacol; 1986; 17(2):171-6. PubMed ID: 3719898
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior.
Lena N; Imbert AM; Pignon T; Favre R; Meyer G; Cano JP; Carcassonne Y
Cancer Chemother Pharmacol; 1984; 12(2):120-4. PubMed ID: 6697425
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T; Takeda T; Yatabe M; Utsumi J; Mimaya J; Ninomiya T; Yanai M
Cancer; 1988 Apr; 61(7):1292-300. PubMed ID: 3278798
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
[TBL] [Abstract][Full Text] [Related]
6. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.
Huang C; Xia F; Xue L; Liu L; Bian Y; Jin Z; Miao L
Cancer Chemother Pharmacol; 2020 Feb; 85(2):433-441. PubMed ID: 31691080
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid.
Morikawa N; Mori T; Abe T; Ghoda M; Takeyama M; Hori S
Ann Pharmacother; 1997 Oct; 31(10):1153-6. PubMed ID: 9337440
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
10. The effect of vindesine on methotrexate hydroxylation in the rat.
Bremnes RM; Smeland E; Slørdal L; Wist E; Aarbakke J
Biochem Pharmacol; 1991 Sep; 42(8):1561-8. PubMed ID: 1930283
[TBL] [Abstract][Full Text] [Related]
11. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies.
Thyss A; Milano G; Deville A; Manassero J; Renee N; Schneider M
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):843-7. PubMed ID: 3477462
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate in acute lymphocytic leukemia.
Freeman AI; Wang JJ; Sinks LF
Cancer Treat Rep; 1977 Jul; 61(4):727-31. PubMed ID: 267510
[TBL] [Abstract][Full Text] [Related]
13. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
14. Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results.
Janka GE; Mack R; Helmig M; Haas RJ; Bidlingmaier F
Oncology; 1984; 41(4):225-32. PubMed ID: 6589560
[TBL] [Abstract][Full Text] [Related]
15. [Administration of vindesine sulfate for the treatment of malignant hematological tumors].
Ueda T; Masaoka T; Shibata H; Kubota Y; Saigo K; Kusakabe H; Takubo T; Nakamura H; Yoshitake J; Ishigami S
Gan To Kagaku Ryoho; 1982 Feb; 9(2):306-15. PubMed ID: 6764103
[TBL] [Abstract][Full Text] [Related]
16. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
17. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia.
Evans WE; Stewart CF; Hutson PR; Cairnes DA; Bowman WP; Yee GC; Crom WR
Drug Intell Clin Pharm; 1982 Nov; 16(11):839-42. PubMed ID: 6959800
[TBL] [Abstract][Full Text] [Related]
18. [Continuous 5-day vindesine in the treatment of leukemias and lymphomas (author's transl)].
Maraninchi D; Gastaut JA; Tubiana N; Carcassonne Y
Bull Cancer; 1981; 68(4):338-42. PubMed ID: 6947833
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma.
Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ
Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
